Literature DB >> 9661695

The red cell transfusion trigger: has a sin of commission now become a sin of omission?

C R Valeri1, J P Crowley, J Loscalzo.   

Abstract

The benefits of a Hct range of 30 to 35 percent include improved oxygen delivery and enhanced hemostasis, which help minimize complications in patients at high risk for ischemia and perioperative nonsurgical bleeding. In these settings, the conservative transfusion practice of using a lower Hct range should be replaced with a more aggressive approach. The known risks of blood transfusion would appear to be sufficiently low and the benefits sufficiently high to justify maintaining a Hct of at least 30 percent. An even higher Hct, of 35 percent, may be desirable in patients who have overt cardiopulmonary disease or who are at high risk for myocardial ischemia. Many retrospective studies have been conducted to persuade us that a conservative transfusion trigger is a safe and prudent practice, but retrospective studies are not what we need. What we need is a series of well-designed, prospective, randomized trials to evaluate the impact of a more aggressive transfusion policy on perioperative mortality, morbidity, and nonsurgical bleeding in patients with known cardiopulmonary disease or who are at high risk for myocardial and cerebrovascular ischemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661695     DOI: 10.1046/j.1537-2995.1998.38698326341.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

Review 1.  [Clinical aspects of packed red cell transfusion. Lessons learned from Jehovah's Witnesses?].

Authors:  B von Bormann
Journal:  Anaesthesist       Date:  2007-04       Impact factor: 1.041

Review 2.  Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.

Authors:  Lise J Estcourt; Reem Malouf; Marialena Trivella; Dean A Fergusson; Sally Hopewell; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2017-01-27

3.  Bone marrow failure following severe injury in humans.

Authors:  David H Livingston; Devashish Anjaria; Jonathan Wu; Carl J Hauser; Victor Chang; Edwin A Deitch; Pranela Rameshwar
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.